RT Journal Article
T1 Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up.
A1 García-Delpech, Salvador
A1 Udaondo, Patricia
A1 Fernández-Santodomingo, Alex Samir
A1 García-Teillard, Damian
K1 Cenegermin
K1 Neurotrophic keratopathy
K1 Recombinant human nerve growth factor
AB The authors report the use of topical recombinant human nerve growth factor cenegermin 0.02% in 5 patients diagnosed with neurotrophic keratopathy (NK) in a real-life setting. These 5 patients affected with stage II and III NK mainly of herpetic cause received cenegermin six times daily for 8 weeks. It was initiated upon refractoriness to prior conventional topical treatment. Visual acuity, corneal sensitivity test at four corneal quadrants, fluorescein staining, OC,T and photography were performed weekly during 9 weeks of follow-up from the completion of treatment. At the ninth week of follow-up, corneal sensitivity improvement and healing of corneal ulcers were found in all patients. No adverse events were reported, and no corneal ulcer recurrence was observed over a 4-year follow-up period. Cenegermin should be used in combination with conventional therapy for advanced NK, as it is an effective treatment for healing corneal ulcers, improving the corneal surface homeostasis and avoiding surgery.
SN 1663-2699
YR 2022
FD 2022-08-31
LK http://hdl.handle.net/10668/20194
UL http://hdl.handle.net/10668/20194
LA en
DS RISalud
RD Apr 11, 2025